Intellia Therapeutics (NTLA) continues to attract attention after recent trading, with the stock closing at $16.84. Investors are weighing this price against the company’s clinical-stage CRISPR pipeline and ongoing collaboration agreements.

While Intellia Therapeutics’ share price slipped 3.38% over the last day and 2.32% over the past week, the 30 day share price return of 24.83% and year to date share price return of 82.84% contrast with a 5 year total shareholder return that declined 88.06%. This suggests recent momentum follows a much weaker longer term record.

If gene editing potential has you looking beyond Intellia Therapeutics, this is a good moment to see what else is moving in healthcare focused AI by checking out 40 healthcare AI stocks.

Bulls argue Intellia Therapeutics’ rebound and the gap with analyst targets point to mispricing, while bears focus on losses and a low value score. To see which side current data supports, the next step is to look closely at valuation.

Most Popular Narrative: 36.8% Undervalued

Against Intellia Therapeutics’ last close at $16.84, the most followed narrative points to a fair value of $26.63, framing the current discount as substantial based on long term forecasts.

The sustained expansion of the addressable market for Intellia's programs is reinforced by demographic trends, especially aging populations and the continued rise in genetic and chronic conditions like ATTR amyloidosis and HAE, supporting higher future patient volumes and underpinning potential multi launch revenue inflection points.

Want to see what is baked into that $26.63 fair value for Intellia Therapeutics? Revenue ramps, margin shifts, and a punchy earnings profile all matter here. The narrative leans on sharp top line expansion, a turn to profitability, and a rich future earnings multiple to justify the gap to today’s price.

Result: Fair Value of $26.63 (UNDERVALUED)

However, the Intellia Therapeutics story can quickly change if late stage trials disappoint or if payer resistance limits uptake of high cost gene editing therapies.

Another View on Intellia Therapeutics’ Valuation

The first narrative leans on long term cash flows and a fair value of $26.63, but the current P/S ratio of 35.6x tells a tougher story. That is well above the US Biotechs industry at 12.4x, the peer average at 23.1x, and the fair ratio estimate of 0.2x, raising questions about valuation risk if sentiment cools.

Before leaning too heavily on any single number, it can help to see how these P/S gaps are broken down and what would need to change for the ratio to move closer to the fair ratio or industry levels: See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on Intellia Therapeutics so far? Act quickly, review the latest data, and form your own view by weighing both the risks and the rewards through the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Intellia Therapeutics?

If you stop with Intellia Therapeutics, you risk missing other opportunities, so use the Simply Wall St screener to quickly spot fresh ideas that match your style.

• Zero in on potential mispricing by hunting for companies that screen as 44 high quality undervalued stocks.
• Strengthen your defensive side by reviewing a 72 resilient stocks with low risk scores that aims to keep volatility in check.
• Get ahead of the crowd by scanning a screener containing 19 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.